Genera Research presented the latest progress in the preclinical and clinical development of OSTEOGROW-C at the 20th Tissue Engineering and Regenerative Medicine International Society (TERMIS) conference, held in Palma de Mallorca from April 20–24, 2026. TERMIS is one of the leading global platforms in the field of tissue engineering and regenerative medicine, bringing together scientists, clinicians, and industry experts from around the world to share advances and foster collaboration. As part of the scientific programme, Genera Research contributed to the session “Advanced biomaterials for bone regeneration”, chaired by Prof. Slobodan Vukičević (Zagreb, Croatia), Prof. Reinhard Windhager (Vienna, Austria), and Dr. Flavia Medeiros Savi (Melbourne, Australia). During the 90-minute session, key milestones in the development of OSTEOGROW technology were presented: Prof. Reinhard Windhager provided an overview of previous clinical trials using different OSTEOGROW formulations. Dr. Nikola Štoković and Dr. Natalia Ivanjko presented preclinical in vitro and in vivo studies on the OSTEOGROW-C formulation. Prof. Slobodan Vukičević concluded the session with a comprehensive overview of the discovery and development of OSTEOGROW, including the regulatory pathway toward a Phase III clinical study. The session also featured presentations from researchers across Europe, including contributions from Finland, Austria, and Italy, highlighting the latest developments in biomaterials for bone regeneration. The conference gathered more than 2,000 participants from across the globe, providing an important platform for scientific exchange and collaboration. The OSTEOGROW-C presentations attracted strong interest from the audience, particularly in the context of its potential as a first-in-class product following Phase III global clinical testing in patients with long bone fracture nonunions. Participation in TERMIS 2026 further reinforces Genera Research’s position at the forefront of regenerative medicine and orthobiologic innovation.

Genera Research Ltd. is participating in the MedTech Innovator Radar Forum 2026, held from April 7–9 in Manhattan Beach, California. The Radar Forum represents a central part of the MedTech Innovator evaluation process, where selected companies present their technologies through live pitch sessions and engage directly with investors, industry leaders, and clinical experts. Insights from these sessions contribute to the final selection of companies for the MedTech Innovator accelerator. MedTech Innovator is recognized as the world’s largest accelerator for medical device, digital health, and diagnostic companies, focused on advancing innovations that improve patient outcomes and transform healthcare globally. Participation in the Radar Forum places Genera Research among a select group of companies developing high-impact medical technologies. On the first day of the event, Genera Research presented its technology, OSTEOGROW-C, in front of four panels of expert judges. The sessions included direct discussions and feedback from investors, strategics, and key decision-makers in the medtech field. The Forum continues over the following days with additional meetings and networking opportunities, providing a valuable platform for further discussions and potential collaborations.